MAXCYTE INC (MXCT) Stock News

NASDAQ:MXCT - US57777K1060 - Common Stock

1.34 USD

0 (0%)

Last: 9/3/2025, 12:52:57 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MXCT Latest News, Press Relases and Analysis

All

Press Releases

23 days ago - By: Yahoo Finance - Mentions: ACET

MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio

23 days ago - By: Benzinga - Mentions: UEIC AI ASPN TTD

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

a month ago - By: Benzinga - Mentions: USPH EBS HAE CCCC ...

12 Health Care Stocks Moving In Thursday's Intraday Session

a month ago - By: The Motley Fool

MaxCyte (MXCT) Q2 Revenue Drops 18%

a month ago - By: Zacks Investment Research - Mentions: IOVA

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

a month ago - By: MaxCyte, Inc

MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

a month ago - By: MaxCyte, Inc

MaxCyte Signs Platform License Agreement with Adicet Bio

a month ago - By: MaxCyte, Inc

MaxCyte Signs Platform License Agreement with Adicet Bio

a month ago - By: MaxCyte, Inc

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

a month ago - By: MaxCyte, Inc

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

2 months ago - By: MaxCyte, Inc

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

2 months ago - By: MaxCyte, Inc

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

3 months ago - By: MaxCyte, Inc

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

3 months ago - By: MaxCyte, Inc

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

4 months ago - By: Yahoo Finance - Mentions: DHI CMG

MaxCyte, Inc. (MXCT): A Bull Case Theory

4 months ago - By: Zacks Investment Research - Mentions: CUE

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

4 months ago - By: MaxCyte, Inc

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

5 months ago - By: MaxCyte, Inc

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

5 months ago - By: MaxCyte, Inc

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

6 months ago - By: MaxCyte, Inc

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

7 months ago - By: MaxCyte, Inc

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

7 months ago - By: MaxCyte, Inc

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

7 months ago - By: MaxCyte, Inc

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

7 months ago - By: MaxCyte, Inc

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

7 months ago - By: Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

7 months ago - By: MaxCyte, Inc

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

7 months ago - By: MaxCyte, Inc

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

7 months ago - By: MarketBeat - Mentions: META AAPL DUK NRG ...

MarketBeat Week in Review – 01/20 - 01/24

7 months ago - By: MarketBeat - Mentions: VRTX CRSP

MaxCyte: Building the Future of Cell and Gene Therapy Innovation